Mark N Kirstein

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Lung Cancer 58:196-204. 2007
  2. ncbi request reprint Exposure-response relationships for oxaliplatin-treated colon cancer cells
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    Anticancer Drugs 19:37-44. 2008
  3. ncbi request reprint Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, 308 Harvard St SE, Minneapolis, MN 55455, USA
    Cancer Chemother Pharmacol 61:291-9. 2008
  4. ncbi request reprint High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 308 Harvard St SE, Minneapolis, 55455, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 835:136-42. 2006
  5. ncbi request reprint Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, Minneapolis 55455, USA
    Breast Cancer Res Treat 96:217-25. 2006
  6. doi request reprint Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system
    Brent W Williams
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, 717 Delaware St SE, Minneapolis, MN 55414, USA
    Cancer Lett 284:37-46. 2009
  7. pmc Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine
    Amit Khatri
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, 55455, USA
    AAPS J 14:1-9. 2012
  8. doi request reprint Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors
    Amit K Mitra
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
    Pharmacogenomics 13:1009-21. 2012
  9. doi request reprint Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU
    Alexey Benyumov
    Department of Medicine, Medical School, University of Minnesota, Minneapolis, Minnesota 55414, USA
    ChemMedChem 6:457-64. 2011
  10. doi request reprint Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors
    Satya V Bommakanti
    Department of Medicine, Division of Hematology, Oncology and Transplantation, Comprehensive Cancer Center, University of Minnesota, Minneapolis, USA
    Am J Clin Oncol 34:597-602. 2011

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Lung Cancer 58:196-204. 2007
    ..0085). In conclusion, gemcitabine infused by this novel method induced apoptosis after both the short and continuous infusions, and long-term survival was significantly diminished following continuous compared with the short infusion...
  2. ncbi request reprint Exposure-response relationships for oxaliplatin-treated colon cancer cells
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    Anticancer Drugs 19:37-44. 2008
    ..5 h. Cell kill effects are reliant on treatment length; hence, the choice of time exposure must be made with a view to maintaining a balance between the cell kill effects and the clinical feasibility of treating the patient...
  3. ncbi request reprint Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, 308 Harvard St SE, Minneapolis, MN 55455, USA
    Cancer Chemother Pharmacol 61:291-9. 2008
    ..The aim of this study was to assess for gemcitabine-induced cell death following infusion of drug under clinically-relevant conditions of infusion rate and drug exposure in an in vitro bioreactor system...
  4. ncbi request reprint High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 308 Harvard St SE, Minneapolis, 55455, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 835:136-42. 2006
    ..With one method we can measure gemcitabine in both plasma and tissue culture media. Utility is demonstrated by evaluation of the disposition of gemcitabine in an in vitro bioreactor cell culture system...
  5. ncbi request reprint Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, Minneapolis 55455, USA
    Breast Cancer Res Treat 96:217-25. 2006
    ..003). In conclusion, gemcitabine concentration-time profiles could be accurately controlled through dosage, infusion rate, and pump flow rate, and cells could be recovered afterward to evaluate drug treatment...
  6. doi request reprint Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system
    Brent W Williams
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, 717 Delaware St SE, Minneapolis, MN 55414, USA
    Cancer Lett 284:37-46. 2009
    ..We conclude that cap-dependent translation blockade and fixed dose rate infusion gemcitabine treatment results in a significant interaction affecting cell viability in vitro...
  7. pmc Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine
    Amit Khatri
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, 55455, USA
    AAPS J 14:1-9. 2012
    ..11 to 0.64 (day(-1)), and statistical significance was generally dependent on cell line and PQIP concentration. These data indicate that treatment with Gemcitabine first, followed by PQIP is superior to the reverse sequence in vitro...
  8. doi request reprint Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors
    Amit K Mitra
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
    Pharmacogenomics 13:1009-21. 2012
    ..The aim of this study was to evaluate the association of gemcitabine pathway SNPs with detailed pharmacokinetic measures obtained from solid tumor patients receiving gemcitabine-based therapy...
  9. doi request reprint Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU
    Alexey Benyumov
    Department of Medicine, Medical School, University of Minnesota, Minneapolis, Minnesota 55414, USA
    ChemMedChem 6:457-64. 2011
    ..Such analyses are expected to provide insight into the beneficial or harmful effect(s) of metabolites towards parent drug activity...
  10. doi request reprint Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors
    Satya V Bommakanti
    Department of Medicine, Division of Hematology, Oncology and Transplantation, Comprehensive Cancer Center, University of Minnesota, Minneapolis, USA
    Am J Clin Oncol 34:597-602. 2011
    ....
  11. ncbi request reprint Molecular targets in the inhibition of angiogenesis
    Arkadiusz Z Dudek
    Division of Hematology, Oncology and Transplantation, Department of Medicine and Comprehensive Cancer Center, 420 Delaware Street, MMC 480, University of Minnesota, Minneapolis, MN 55455, USA
    Expert Opin Ther Targets 7:527-41. 2003
    ....
  12. doi request reprint Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors
    Kyle Jensen
    College of Pharmacy, Department of Experimental and Clinical Pharmacology, University of Minnesota, 308 Harvard St SE, Minneapolis, MN, USA
    Naunyn Schmiedebergs Arch Pharmacol 385:519-25. 2012
    ..Therefore, activation of these receptors may be at least one mechanism through which fludarabine-associated toxicity occurs...
  13. doi request reprint Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines
    Pawel Zwolak
    Department of Orthopaedic Surgery, University of Minnesota Medical School and Masonic Cancer Center, 2450 Riverside Avenue, R200, Minneapolis, MN 55454, USA
    J Bone Joint Surg Am 92:162-8. 2010
    ..The aim of this study was to analyze the elution dynamics of zoledronic acid release from acrylic bone cement and its in vitro antitumor efficacy...
  14. ncbi request reprint Review of selected patents for cancer therapy targeting tumor angiogenesis
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Recent Pat Anticancer Drug Discov 1:153-61. 2006
    ....
  15. doi request reprint Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C
    Natasha M Rueth
    Division of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA
    Ann Surg Oncol 18:174-80. 2011
    ..Our aim was to review electrolyte disturbances and complications after HIPC with oxaliplatin (OX) versus mitomycin C (MMC)...
  16. doi request reprint Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid
    Amit Khatri
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA
    Cancer Chemother Pharmacol 68:721-31. 2011
    ..This study evaluated the effect of cranial radiation on the pharmacokinetics of irinotecan in plasma and cerebrospinal fluid (CSF)...
  17. ncbi request reprint A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  18. ncbi request reprint A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors
    Victor M Santana
    Department of Hematology, St Jude Children s Research Hospital, University of Tennessee, Memphis, Tennessee 38103, USA
    Clin Cancer Res 9:633-40. 2003
    ..To assess the use of a pharmacokinetically guided topotecan strategy and evaluate the toxicity of protracted i.v. topotecan in children with recurrent solid tumors...
  19. ncbi request reprint Topoisomerase I interactive agents
    Mark N Kirstein
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Cancer Chemother Biol Response Modif 20:99-123. 2002
    ..However, it is essential that these agents have the proper preclinical studies performed and that they be rationally developed...
  20. ncbi request reprint Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors
    John C Panetta
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Cancer Chemother Pharmacol 52:435-41. 2003
    ..To construct a population pharmacokinetic model for temozolomide (TMZ), a novel imidazo-tetrazine methylating agent and its metabolites MTIC and AIC in infants and children with primary central nervous system tumors...
  21. ncbi request reprint Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection
    Feng Bai
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, 38105, Memphis, TN, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 784:225-32. 2003
    ..With one method we can measure lactone and total TPT and NDS with adequate sensitivity to allow for evaluation of the disposition of these compounds in children receiving TPT...
  22. ncbi request reprint Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC
    Mark N Kirstein
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Cancer Chemother Pharmacol 55:433-8. 2005
    ..To develop a pharmacokinetic limited sampling model (LSM) for temozolomide and its metabolite MTIC in infants and children...
  23. ncbi request reprint New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065
    Feng Bai
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 772:257-65. 2002
    ..Furthermore, the application of a coulometric electrode is more efficient and requires less maintenance than previously published methods for the two compounds...